Business Wire

SMITHS-DETECTION

10.10.2019 08:02:08 CEST | Business Wire | Press release

Share
Smiths Detection Showcases Biometric Checkpoint Solution at inter airport Europe 2019

Global threat detection and security technologies company, Smiths Detection is showcasing for the first time an integrated checkpoint solution at inter airport Europe 2019, which harnesses biometric technology to enable risk-based screening practices.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191009005541/en/

With air passenger growth predicted to double by 2037, the aviation industry will be challenged to support this capacity growth whilst providing operational efficiencies and meeting shifting passenger expectations of the airport experience.1 To cope with this growth, biometric technology is being increasingly adopted at airport Border Control gates, bag drop and boarding gates.

As leaders in providing checkpoint solutions to airports across the world, Smiths Detection has partnered with experts in the field of biometry to, for the first time, create a proof of concept which integrates biometric identity management solutions with class-leading screening solutions. Inter airport delegates are invited to experience the biometric capable checkpoint in action – which also employs Smiths Detection’s advanced CT scanner, HI-SCAN 6040 CTiX , the iCMORE Weapons automatic object recognition capability and the advanced tray return system, iLane.evo .

Biometrics is the ‘unique identifier’ for passengers, and through integration of biometrics directly into the checkpoint, passengers can be matched with their trays to enable real-time risk-based screening. Risk-based screening is designed to increase operational efficiency and effectiveness through continual risk assessments relevant to the individual passenger journey, resulting in shorter and easier journeys for passengers.

Through passenger and tray identification, new data insights can be gathered to inform decision making at airports - based on flights, airlines or destinations. Matching passengers with trays also enables the sharing of screening results with transit or arrival airports, and the combination of hold baggage and checkpoint screening results.

“At Smiths Detection, we’re dedicated to delivering a seamless passenger journey and we are very excited to be driving biometric checkpoint technology forward in a rapidly developing marketplace,” said Smiths Detection Vice President Europe, Africa and Marketing Tony Tielen . “As a trusted partner to airports across the world, we are working with the aviation industry to deliver risk-based screening at departure, transit and arrival airports to streamline the checkpoint journey to make it even safer and more efficient.”

“Biometrics is an urgently needed solution to provide seamless checkpoint security,” said Global Market Director Aviation, Richard Thompson . “Ever increasing air passenger traffic plus advances in biometrics, artificial intelligence and integrated screening technology mean that risk-based screening is now firmly on the fast track. We look forward to offering a preview of the checkpoint solution of the future to delegates at inter airport Europe 2019.”

Enquiries:

If you would like to speak with someone regarding this press release and/or preview this checkpoint solution, Smiths Detection will be presenting at Stand 410, Hall B6 at inter airport Europe.

References and data points:

  • At the beginning of 2018, SITA, the airlines technology supplier, reported that 77% of airports and 71% of airlines were planning major programs or R&D in biometric ID management over the next five years.
  • Airlines are responding to demands from passengers as 57% of passengers would "definitely use biometrics" if it helps them get quicker through the boarding process, according to SITA.
  • According to the IATA 2018 Passenger Survey , 45% of air travellers choose biometric identification as a replacement of their passport.
  • Over 65 percent of passenger’s were inclined towards sharing additional personal information to speed up their processing at the airport. Speed and convenience are paramount, according to IATA .

Recent press releases:

###

About Smiths Detection

Smiths Detection is a global leader in threat detection and screening technologies for aviation, ports and borders, urban security and defence. With more than 40 years of field-tested experience, we deliver the solutions needed to protect society from the threat and illegal passage of explosives, prohibited weapons, contraband, toxic chemicals and narcotics.

Our mission is to help make the world a safer place – and do this by using technology to develop innovative solutions and services which protect life, safeguard society and uphold the free flow of trade.

For more information visit http://www.smithsdetection.com .

About inter airport Europe

From 8 – 11 October 2019, inter airport Europe 2019, the 22nd International Exhibition for Airport Equipment, Technology, Design and Services will take place at the Munich Trade Fair Centre in Germany.

For manufacturers and suppliers of airport equipment, technology, design and services, inter airport Europe provides the opportunity to meet specialists from airports, airlines, air cargo carriers as well as aviation support from all over the world looking to invest in future-oriented, modern solutions for the interconnected airport. The world’s leading airport exhibition is renowned for covering the most comprehensive range of products and services for the entire airport: technology and services for ground handling, airport equipment, terminal operations, airport IT solutions and airport design.

For more information visit https://www.interairporteurope.com/welcome#/


1 https://www.iata.org/pressroom/pr/Pages/2018-10-24-02.aspx

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release

Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P

Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release

Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result

Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release

Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said

SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release

In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin

Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release

Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye